Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3Vidofludimus CalciumPositive

AI Analysis

Summary

Immunic, Inc. reported Q2 2026 financial results and expanded its leadership team with new appointments in CEO, CMO, and Board Chair roles to support clinical development and NDA/commercial readiness. The company is advancing pivotal Phase 3 ENSURE trials of Vidofludimus Calcium.

Clinical Trial Data

Phase

Phase 3

Importance:6/10

Sentiment:

0.50

Phase_3_TrialLeadership_AppointmentsNDA_ReadinessClinical_DevelopmentEarnings_Update

Related Companies

$MDCE

Read the original article

Published by PR Newswire Biotech on August 11, 2026 10:30 AM

Read Original